TABLE 1.
Association between ALYREF and clinicopathologic characteristics of the 162 bladder cancer patients
| ALYREF expression [cases (%)] | ||||
|---|---|---|---|---|
| Parameter | Total [cases (%)] | Low | High | P value |
| Total | 162 | 123 (75.9) | 39 (24.1) | |
| Gender | 0.203 | |||
| Male | 125 (77.2) | 92 (74.8) | 33 (84.6) | |
| Female | 37 (22.8) | 31 (25.2) | 6 (15.4) | |
| Age at surgery (years) | 0.177 | |||
| ≥ 65 | 94 (58.0) | 75 (61.0) | 19 (48.7) | |
| < 65 | 68 (42.0) | 48 (39.0) | 20 (51.3) | |
| Pathological stage | 0.612 | |||
| pT2‐T4 | 41 (25.3) | 17 (13.8) | 24 (61.5) | |
| pTa‐T1 | 121 (74.7) | 106 (86.2) | 15 (38.5) | |
| Grade | 0.135 | |||
| High | 87 (53.7) | 62 (50.4) | 25 (64.1) | |
| Low | 75 (46.3) | 61 (49.6) | 14 (35.9) | |
| Tumor size (cm) | 0.017 | |||
| ≥ 4 | 65 (40.1) | 43 (35.0) | 22 (56.4) | |
| < 4 | 97 (59.9) | 80 (65.0) | 17 (43.6) | |
| Lymph node metastasis | 0.021 | |||
| Present | 47 (29.0) | 30 (24.4) | 17 (43.6) | |
| Absent | 115 (71.0) | 93 (75.6) | 22 (56.4) | |
| PKM2 expression | 0.044 | |||
| Low | 85 (52.5) | 70 (56.9) | 15 (38.5) | |
| High | 77 (47.5) | 53 (43.1) | 24 (61.5) | |
Abbreviations: ALYREF, Aly/REF export factor; PKM2, pyruvate kinase muscle isozyme M2.